{"title": "Moderna", "page_id": 39743243, "revision_id": 1265085948, "revision_timestamp": "2024-12-25T01:05:40Z", "content": "{{cs1 config|name-list-style=vanc}}\n{{short description|American biotechnology company}}\n{{coord|42.3633|-71.091|display=title}}\n{{Use mdy dates|date=November 2020}}\n{{Use American English|date=November 2020}}\n{{Infobox company\n| name = Moderna, Inc.\n| logo = Moderna logo.svg\n| image = Moderna Headquarters, December 2020.jpg\n| image_caption = Moderna headquarters in [[Cambridge, Massachusetts]]\n| type = [[Public company|Public]]\n| traded_as = {{ubl|{{NASDAQ|MRNA}}|[[S&P 500]] component}}\n| ISIN = {{ISIN|sl=n|pl=y|US60770K1079}}\n| former_name = ModeRNA Therapeutics<br />(2010\u20132018)\n| founded = {{start date and age|2010|9}}\n| founders = {{ubl|[[Derrick Rossi]] | [[Timothy A. Springer]] |[[Robert S. Langer]] | [[Kenneth R. Chien]] | [[Noubar Afeyan]]}}\n| hq_location = 200 [[Technology Square (Cambridge, Massachusetts)|Technology Square]]<br>[[Cambridge, Massachusetts]], U.S.\n| industry = [[Biotechnology]]\n| key_people = {{Ubl|[[St\u00e9phane Bancel]] ([[Chief executive officer|CEO]]) | [[Noubar Afeyan]] ([[chairman]]) | Stephen Hoge ([[President (corporate title)|president]]) | David Meline ([[Chief financial officer|CFO]])}}\n| products = {{unbulleted list|[[Moderna COVID-19 vaccine|Spikevax]]|[[Vaccine]] candidates}}\n| revenue = {{decrease}} {{US$|6.848 billion|link=yes}}\n| revenue_year = 2023\n| operating_income = {{decrease}} {{US$|-4.24 billion}}\n| income_year = 2023\n| net_income = {{decrease}} {{US$|-4.71 billion}}\n| net_income_year = 2023\n| assets = {{decrease}} {{US$|18.43 billion}}\n| assets_year = 2023\n| equity = {{decrease}} {{US$|13.85 billion}}\n| equity_year = 2023\n| num_employees = 5,600\n| num_employees_year = 2023\n| owners = {{unbulleted list|[[St\u00e9phane Bancel]] (7.3%)|[[Noubar Afeyan]] (5.0%)|[[Robert S. Langer]] (4.0%)|Stephen Hoge (1.3%)}}\n| website = {{URL|modernatx.com}}\n| footnotes = <ref name=10K /><ref>{{Cite web | url=https://www.sec.gov/ix?doc=/Archives/edgar/data/0001682852/000130817923000184/lmrna2023_def14a.htm | title=Moderna, Inc. Schedule 14A 2022 Proxy Statement | publisher=[[U.S. Securities and Exchange Commission]] | date=March 9, 2022}}</ref><ref>{{cite web | url=https://www.modernatx.com/about-us/moderna-facts | title=Key Facts | website=Moderna}}</ref>\n}}\n\n'''Moderna, Inc.''' ({{IPAc-en|m|\u0259|\u02c8|d|\u025c\u02d0r|n|\u0259}} {{respell|m\u0259|DUR|n\u0259}})<ref>{{cite AV media | author=Moderna | date=October 23, 2019 | title=mRNA-3704 and Methylmalonic Acidemia | url=https://www.youtube.com/watch?v=eb8OHaF8wio | medium=[[video]] | via=[[YouTube]]}}</ref> is an American pharmaceutical and [[biotechnology]] company based in [[Cambridge, Massachusetts]], that focuses on [[RNA therapeutics]], primarily [[mRNA vaccine]]s. These [[vaccine]]s use a copy of a molecule called [[messenger RNA]] (mRNA) to carry instructions for proteins to produce an [[immune response]].<ref>{{cite journal |vauthors=Park KS, Sun X, Aikins ME, Moon JJ |date=December 2020 |title=Non-viral COVID-19 vaccine delivery systems |journal=[[Advanced Drug Delivery Reviews]] |volume=169 |pages=137\u201351 |doi=10.1016/j.addr.2020.12.008 |pmc=7744276 |pmid=33340620}}</ref><ref name=10K>{{cite web | url=https://www.sec.gov/ix?doc=/Archives/edgar/data/1682852/000168285224000015/mrna-20231231.htm | title=Moderna, Inc., 2023, Form 10-K Annual Report | publisher=[[U.S. Securities and Exchange Commission]] |date=February 23, 2024}}</ref> The company's name is derived from the  terms \"modified\", \"RNA\", and \"modern\".<ref name=moderna-about>{{cite web |title=Moderna, Our story; Our big moments |url=https://www.modernatx.com/en-US/about-us/our-story |publisher=Moderna, Inc. |access-date=10 February 2023 |date=2023}}</ref><ref name=stat-story>{{Cite news | last1=Garde | first1=Damian | last2=Saltzman | first2=Jonathan | work=[[Stat (website)|Stat]] | date=November 10, 2020 | title=The story of mRNA: How a once-dismissed idea became a leading technology in the Covid vaccine race | url=https://www.statnews.com/2020/11/10/the-story-of-mrna-how-a-once-dismissed-idea-became-a-leading-technology-in-the-covid-vaccine-race/ | url-status=live | archive-url=https://web.archive.org/web/20201110183905/https://www.statnews.com/2020/11/10/the-story-of-mrna-how-a-once-dismissed-idea-became-a-leading-technology-in-the-covid-vaccine-race/ | archive-date=November 10, 2020}}</ref><ref name=\"servick\">{{cite journal |last=Servick |first=Kelly |date=25 March 2020 |title=This mysterious $2 billion biotech is revealing the secrets behind its new drugs and vaccines (from the original, 1 February 2017) |url=https://www.science.org/content/article/mysterious-2-billion-biotech-revealing-secrets-behind-its-new-drugs-and-vaccines |journal=[[Science (journal)|Science]] |doi=10.1126/science.aal0686 |s2cid=241466550}}</ref>\n\nThe company's commercial products are the [[Moderna COVID-19 vaccine]], marketed as Spikevax and a RSV vaccine, marketed as Mresvia. The company has 44 treatment and vaccine candidates, of which 37 have entered [[clinical trial]]s. Candidates include possible vaccines for [[influenza]], [[HIV]], [[Epstein\u2013Barr virus]], the [[Nipah virus]], [[chikungunya]], [[human metapneumovirus]], [[varicella zoster virus]], as well as a [[cytomegalovirus vaccine]], a [[Zika virus vaccine]] funded by the [[Biomedical Advanced Research and Development Authority]], and three [[cancer vaccine]]s. The company's pipeline also includes a [[cell therapy]]-based treatment: a [[relaxin]] [[fusion protein]] being developed to treat [[acute decompensated heart failure]]. It also includes candidates that use [[OX40 ligand]], [[interleukin 23]], [[IL36G]], and [[interleukin 12]] for [[cancer immunotherapy]],  specifically treatment of [[breast cancer]], [[urothelial carcinoma]], [[lymphoma]], and [[melanoma]]. Also being developed by Moderna is a [[regenerative medicine]] treatment that encodes [[vascular endothelial growth factor A]] to stimulate [[blood vessel]] growth for patients with [[myocardial ischemia]].<ref name=10K/>{{Failed verification|date=May 2024|reason=could not find mention of the therapeutic in source}}\n\n==History==\nModerna was founded in 2010 by [[Derrick Rossi]], [[Timothy A. Springer]], [[Kenneth R. Chien]], [[Robert S. Langer]], and [[Noubar Afeyan]].<ref>{{cite news | url=https://www.bostonmagazine.com/health/2013/02/26/moderna-therapeutics-new-medical-technology/ | date=March 2013 | title=The NEXT Next Big Thing | first=Catherine | last=Elton | work=[[Boston Magazine]] | archive-date=November 16, 2020 |archive-url=https://web.archive.org/web/20201116154152/https://www.bostonmagazine.com/health/2013/02/26/moderna-therapeutics-new-medical-technology/ | url-status=live}}</ref> [[St\u00e9phane Bancel]], the current CEO, was appointed as CEO in 2011.<ref name=moderna-about/><ref name=Ego>{{cite web | url=https://www.statnews.com/2016/09/13/moderna-therapeutics-biotech-mrna/ | title=Ego, ambition, and turmoil: Inside one of biotech's most secretive startups | first=Damien | last=Garde | date=September 13, 2016 | work=[[Stat (website)|Stat]] | archive-date=November 16, 2020 | archive-url=https://web.archive.org/web/20201116154313/https://www.statnews.com/2016/09/13/moderna-therapeutics-biotech-mrna/ | url-status=live}}</ref> Between 2011 and 2017, Moderna raised $2{{spaces}}billion in [[venture capital]] funding.<ref name=stat-story/><ref name=servick/>\n\nIn November 2024, Moderna Inc. announced that St\u00e9phane Bancel, currently serving as Chief Executive Officer, will step down from his role as Chief Commercial Officer while continuing as CEO. Moderna's President, Stephen Hoge, will take over responsibilities for the company's sales, medical, and research affairs.<ref>{{Cite news |date=2024-11-05 |title=Moderna's Bancel Steps Down as Sales Chief, Keeps CEO Role |url=https://www.bloomberg.com/news/articles/2024-11-05/moderna-s-bancel-steps-down-as-sales-chief-keeps-ceo-role?embedded-checkout=true |access-date=2024-11-08 |work=Bloomberg.com |language=en}}</ref>\n\n=== Product development ===\nIn 2013, the company formed a partnership with [[AstraZeneca]] to develop treatments for cardiovascular, metabolic, and renal diseases, as well as cancer. Moderna was also awarded a $25,000,000 grant by DARPA through a program Autonomous Diagnostics to Enable Prevention and Therapeutics: Prophylactic Options to Environmental and Contagious Threats (ADEPT-PROTECT). Its stated goal was to develop an mRNA vaccine with the capability to suppress a global pandemic within 60 days. In January 2014, the company entered an agreement with [[Alexion Pharmaceuticals]] to develop treatments against ten diseases.<ref>{{Cite web |last=Reidy |first=Chris |date=2014-01-13 |title=Alexion, Moderna announce agreement to develop messenger RNA therapeutics |url=https://www.boston.com/news/innovation/2014/01/13/alexion-moderna-announce-agreement-to-develop-messenger-rna-therapeutics/ |url-status=live |archive-url=https://archive.today/20210702151040/https://www.boston.com/news/innovation/2014/01/13/alexion-moderna-announce-agreement-to-develop-messenger-rna-therapeutics/ |archive-date=2021-07-02 |access-date=2023-06-05 |website=[[Boston Globe Media Partners]] |language=en-US}}</ref> On January 14, 2014, Moderna announced the creation of its first venture, Onkaido Therapeutics, to focus \"exclusively on developing mRNA-based oncology treatments.\"<ref>{{Cite press release |publisher=[[PR Newswire]] |date=2014-01-14 |title=Moderna Launches Onkaido Therapeutics to Focus on the Development of mRNA Therapeutics\u2122 in Oncology with $20 Million Capital Commitment |url=https://www.prnewswire.com/news-releases/moderna-launches-onkaido-therapeutics-to-focus-on-the-development-of-mrna-therapeutics-in-oncology-with-20-million-capital-commitment-240111061.html |archive-url=https://web.archive.org/web/20161120035524/http://www.modernatx.com/news-events/press-releases/moderna-launches-onkaido-therapeutics-focus-development-mrna-therapeuticstm |archive-date=2016-11-20 | url-status=live}}</ref><ref>{{Cite news |last=Gormley |first=Brian |date=2014-01-15 |title=Moderna Launches Cancer Drug Co. Onkaido Therapeutics With $20M Investment |language=en-US |work=[[Wall Street Journal]] |url=http://www.wsj.com/articles/DJFVW00020140114ea1eqwhzn |access-date=2023-06-05 |archive-url=https://web.archive.org/web/20230605073740/https://www.wsj.com/articles/DJFVW00020140114ea1eqwhzn |archive-date=2023-06-05 |issn=0099-9660}}</ref> It launched its second venture, Valera, in January 2015, with a focus on \"viral, bacterial and parasitic infectious diseases.\"<ref>{{Cite press release | publisher=[[PR Newswire]] |date=January 8, 2015 |title=Moderna Launches New Venture Valera LLC for Infectious Diseases |url=https://www.prnewswire.com/news-releases/moderna-launches-new-venture-valera-llc-for-infectious-diseases-300017587.html |archive-url=https://web.archive.org/web/20161119214315/http://www.modernatx.com/news-events/press-releases/moderna-launches-new-venture-valera-llc-infectious-diseases |archive-date=2016-11-19 | url-status=live}}</ref><ref>{{Cite web |date=2015-01-12 |title=Moderna Launches New Venture Valera LLC for Infectious Diseases |url=https://www.bionity.com/en/news/151144/moderna-launches-new-venture-valera-llc-for-infectious-diseases.html |url-status=live |archive-url=https://archive.today/20230605165153/https://www.bionity.com/en/news/151144/moderna-launches-new-venture-valera-llc-for-infectious-diseases.html |archive-date=2023-06-05 |access-date=2023-06-05 |website=Bionity |language=en}}</ref> Employees of Valera and Moderna developed an mRNA vaccine candidate against [[Zika virus]] infection.<ref>{{Cite journal |last1=Richner |first1=Justin M. |last2=Himansu |first2=Sunny |last3=Dowd |first3=Kimberly A. |last4=Butler |first4=Scott L. |last5=Salazar |first5=Vanessa |last6=Fox |first6=Julie M. |last7=Julander |first7=Justin G. |last8=Tang |first8=William W. |last9=Shresta |first9=Sujan |last10=Pierson |first10=Theodore C. |last11=Ciaramella |first11=Giuseppe |last12=Diamond |first12=Michael S. |date=2017-02-17 |title=Modified mRNA Vaccines Protect against Zika Virus Infection |url=|journal=Cell |volume=168 |issue=6 |pages=1114\u20131125.e10 |doi=10.1016/j.cell.2017.02.017 |issn=0092-8674 |pmc=5388441 |pmid=28222903}}</ref> Another venture, Elpidera, was announced in May 2015 to continue work on RNA therapies advancing Moderna's work with Alexion.<ref>{{Cite press release | publisher=[[PR Newswire]] |date=May 12, 2015 |title=Moderna Launches Third Venture Company Elpidera for Rare Diseases  |url=https://www.prnewswire.com/news-releases/moderna-launches-third-venture-company-elpidera-for-rare-diseases-300081336.html |archive-url=https://web.archive.org/web/20161012234942/http://www.modernatx.com/news-events/press-releases/moderna-launches-third-venture-company-elpidera-rare-diseases |archive-date=2016-10-12 | url-status=live}}</ref><ref>{{Cite web |last=Tirrell |first=Meg |date=2015-05-12 |title=The biotech targeting personalized medicine |url=https://www.cnbc.com/2015/05/12/moderna-therapeutics-is-trying-to-cure-disease-with-mrna-drugs.html |url-status=live |archive-url=https://archive.today/20210410143842/https://www.cnbc.com/2015/05/12/moderna-therapeutics-is-trying-to-cure-disease-with-mrna-drugs.html |archive-date=2021-04-10 |access-date=2023-06-05 |website=[[CNBC]] |language=en}}</ref>\n\nIn 2015, the company formed a partnership with [[Merck & Co.]] to develop treatments for cancer, and in 2016 the company formed a partnership with [[Vertex Pharmaceuticals]] to develop treatments for [[cystic fibrosis]].<ref name=\"Ego\" /><ref name=\"Globe\">{{cite news | title=Moderna in line for $240m licensing deal | work=[[The Boston Globe]] | first=Robert | last=Weisman | date=March 21, 2013 | url-access=limited | url=https://www.bostonglobe.com/business/2013/03/20/moderna-therapeutics-receive-million-license-its-technology-drug-giant-astrazeneca/VAFlMn2lZaCDZ6A0oyHKSI/story.html | archive-date=November 16, 2020 | archive-url=https://web.archive.org/web/20201116154149/https://www.bostonglobe.com/business/2013/03/20/moderna-therapeutics-receive-million-license-its-technology-drug-giant-astrazeneca/VAFlMn2lZaCDZ6A0oyHKSI/story.html | url-status=live}}</ref><ref>{{cite web |title=Moderna: Strategic collaborators |url=https://www.modernatx.com/partnerships/strategic-collaborators? |publisher=Moderna, Inc. |access-date=11 February 2023 |date=2023}}</ref><ref>{{cite web |title=Vertex and Moderna hammer out $315 million+ deal to treat cystic fibrosis using mRNA technology |url=https://www.biospace.com/article/vertex-and-moderna-hammer-out-315-million-deal-to-treat-cystic-fibrosis-using-mrna-technology-/ |publisher=BioSpace |access-date=11 February 2023 |date=6 July 2016}}</ref> In January 2016, the [[Bill & Melinda Gates Foundation]] committed to provide at least $20 million in [[Grant (money)|grant]] funding to the company.<ref name=\"10K\" /> In 2017, Alexion terminated its partnership with Moderna after safety issues prevented their work from reaching human trials.<ref>{{Cite news | url=https://www.statnews.com/2017/07/27/moderna-alexion-partnership/ | title=Key partner cuts ties with brash biotech startup Moderna, raising big questions about its pipeline | first=Damian | last=Garde | work=[[Stat (website)|Stat]] | date=July 27, 2017}}</ref> \n\nIn July 2018, the company opened a 200,000 square foot facility in [[Norwood, Massachusetts]] for manufacturing, preclinical and clinical work.<ref>{{Cite news | url=https://www.bizjournals.com/boston/news/2018/07/17/modernas-110m-norwood-site-built-with-expansion.html | title=Moderna's $110M Norwood site built with expansion hopes | first=Allison | last=DeAngelis | work=[[American City Business Journals]] | date=July 17, 2018}}</ref> In December 2018, Moderna became a [[public company]] via the largest [[initial public offering]] of a biotechnology company in history, raising $621{{spaces}}million by selling 27 million shares at $23 per share.<ref>{{cite news | url=https://fortune.com/2018/12/08/moderna-ipo-biotech-future/ | first=Sy | last=Mukherjee | work=[[Fortune (magazine)|Fortune]] | title=Moderna Had the Biggest Biotech IPO Ever. Here's What That Says About the Industry's Future | date=December 8, 2018 | archive-date=November 16, 2020 | archive-url=https://web.archive.org/web/20201116154242/https://fortune.com/2018/12/08/moderna-ipo-biotech-future/ | url-status=live}}</ref><ref>{{cite web | url=https://www.businessinsider.com/biotech-moderna-prices-initial-public-offering-2018-12 | title=Moderna just priced the biggest IPO in biotech history, valuing the startup at $7.5 billion | first=Lydia | last=Ramsey | work=[[Business Insider]] | date=December 7, 2018 | archive-date=November 16, 2020 | archive-url=https://web.archive.org/web/20201116154155/https://www.businessinsider.com/biotech-moderna-prices-initial-public-offering-2018-12?r=US&IR=T | url-status=live}}</ref>\n\nThe first mRNA vaccine developed by Moderna was for [[influenza]] in 2015, and its first [[antibody]] encoded by mRNA was in 2019.<ref name=moderna-about/> In 2023, Moderna acquired OriCiro Genomics, a Japanese manufacturer of [[genetic engineering]] tools, in its first acquisition.<ref>{{cite web | first=Hayden | last=Schmidt |url=https://pharmanewsintel.com/news/moderna-to-buy-japanese-firm-oriciro-in-its-first-ever-acquisition |publisher=PharmaNews Intelligence |title=Moderna to Buy Japanese Firm OriCiro in Its First-Ever Acquisition |date=5 January 2023}}</ref>\n\nIn early 2023, the company in collaboration with [[Merck & Co.|Merck]] won [[Breakthrough therapy|breakthrough status]] from the FDA for its [[mRNA-4157/V940]] drug candidate, a [[cancer vaccine]].<ref name=\"natmed1\">{{cite journal  | title=Precision medicine meets cancer vaccines |journal=[[Nature Medicine]] | date=16 June 2023| volume=29 | issue=6 | page=1287 | doi=10.1038/s41591-023-02432-2 | pmid=37328586 | s2cid=259184146 | doi-access=free }}</ref><ref>{{cite journal | last1=Bafaloukos|first1=Dimitrios |date=2023|title=Evolution and Progress of mRNA Vaccines in the Treatment of Melanoma: Future Prospects|journal=[[List of MDPI academic journals#V|Vaccines]]|volume= 11|issue= 3|page=636 |doi=10.3390/vaccines11030636|pmid=36992220 |pmc=10057252 |doi-access=free }}</ref>\n\nIn July 2023, the company entered into an agreement with the Chinese government to develop mRNA drugs for exclusive use in [[China]].<ref>{{Cite news |url=https://www.ft.com/content/a9e9bc51-34a9-455c-a7ae-7b9f8c4cb15a |last1=Kuchler |first1=Hannah |last2=Mancini |first2=Donato Paolo  |title=US biotech Moderna strikes deal to develop mRNA drugs in China |work=Financial Times | date=July 5, 2023}}</ref>\n\nIn May 2024, the mRNA vaccine Mresvia was approved for medical use in the United States by the US [[Food and Drug Administration]] (FDA) for the prevention of lower respiratory tract disease caused by [[respiratory syncytial virus]] in individuals 60 years of age and older,<ref>{{cite press release | title=Moderna Receives U.S. FDA Approval for RSV Vaccine Mresvia | publisher=Moderna | via=Accesswire | date=31 May 2024 | url=https://www.accesswire.com/870069/moderna-receives-us-fda-approval-for-rsv-vaccine-mresvia | access-date=31 May 2024}}</ref><ref name=\"FDA PR 20240531\">{{cite press release | title=FDA Roundup: May 31, 2024 | website=U.S. [[Food and Drug Administration]] (FDA) | date=31 May 2024 | url=https://www.fda.gov/news-events/press-announcements/fda-roundup-may-31-2024 | access-date=31 May 2024}} {{PD-notice}}</ref> the third [[Respiratory syncytial virus vaccine|RSV vaccine]] approved in the United States.\n\n===COVID-19 vaccine===\n{{Main|Moderna COVID-19 vaccine}}\nFrom 2020 to 2021, Moderna received $955{{spaces}}million from [[Operation Warp Speed]] to accelerate development of its COVID-19 vaccine, with $4.9{{spaces}}billion committed in total for producing 300 million vaccine doses.<ref>{{cite web | first=Miriam | last=Valverde |title=How Pfizer's and Moderna's COVID-19 vaccines are tied to Operation Warp Speed |url=https://www.politifact.com/article/2020/nov/19/pfizer-moderna-covid-19-vaccines-and-operation-war/ |publisher=PolitiFact |access-date=12 February 2023 |date=19 November 2020}}</ref><ref>{{cite web |title=Operation Warp Speed Contracts for COVID-19 Vaccines and Ancillary Vaccination Materials |url=https://crsreports.congress.gov/product/pdf/IN/IN11560| first=Simi V. | last=Siddalingaiah |publisher=Congressional Research Service, United States Government|access-date=12 February 2023 |date=1 March 2021}}</ref>\n\nIn March 2020, the [[Food and Drug Administration]] approved [[clinical trial]]s for the [[Moderna COVID\u201119 vaccine]] candidate, and in December, the vaccine, mRNA-1273, was issued an [[emergency use authorization]] in the United States.<ref>{{cite news | title=Statement from NIH and BARDA on the FDA Emergency Use Authorization of the Moderna COVID-19 Vaccine | url=https://www.nih.gov/news-events/news-releases/statement-nih-barda-fda-emergency-use-authorization-moderna-covid-19-vaccine | publisher=[[National Institutes of Health]] | date=December 18, 2020}}</ref><ref>{{cite journal | title=Moderna COVID vaccine becomes second to get US authorization | journal=Nature | date=2020-12-18 | doi=10.1038/d41586-020-03593-7 | url=https://www.nature.com/articles/d41586-020-03593-7 | access-date=2023-02-12| last1=Ledford | first1=Heidi | pmid=33340017 | s2cid=243212854 }}</ref> In 2022, it gained FDA approval both for the [[Vaccine#Valence|monovalent vaccine]], ''Spikevax'', and a bivalent [[booster shot|booster]].<ref>{{cite web |title=Moderna COVID-19 vaccines |url=https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccines |publisher=US Food and Drug Administration |access-date=11 February 2023 |date=15 December 2022}}</ref>\n\nIn April 2022, Moderna announced plans to build a $180 million vaccine factory in [[Montreal]], forming a 10-year partnership with the [[Government of Canada]], [[Quebec]], and [[McGill University]] to produce 100 million ''Spikevax'' doses annually and expand vaccine research capabilities.<ref>{{cite news |title=Moderna facility in Montreal area expected to produce 100 million vaccine doses by 2024 |url=https://www.cbc.ca/news/canada/montreal/moderna-montreal-facility-mrna-1.6435636 |work=[[CBC News]] |date=29 April 2022}}</ref> The plant is scheduled to supply COVID-19 vaccines in the fall of 2025.<ref>{{Cite web |title=Moderna will supply COVID-19 vaccines made in Laval by fall 2025 |url=https://montrealgazette.com/news/local-news/moderna-will-supply-covid-19-vaccines-made-in-laval-by-fall-2025 |website=The Gazette}}</ref>\n\nIn February 2023, the company agreed to pay $400 million to the [[National Institutes of Health]], [[Dartmouth College]], and [[Scripps Research]] to settle a dispute over the rights to a chemical technique that was used in the vaccine.<ref>{{Cite news | url=https://www.nytimes.com/2023/02/23/science/moderna-covid-vaccine-patent-nih.html | title=After Long Delay, Moderna Pays N.I.H. for Covid Vaccine Technique | first=Benjamin | last=Mueller | work=[[The New York Times]] | date=February 23, 2023 | url-access=limited}}</ref>\n\n[[Arbutus Biopharma]] filed a patent infringement lawsuit against Moderna in 2022, alleging that Arbutus developed lipid nanoparticles that enclose Modern'a vaccine's mRNA payload.<ref name=\":0\">{{Cite news |date=2024-04-03 |title=Moderna shares fall after judge sides with Arbutus in patent fight |url=https://www.reuters.com/legal/moderna-shares-fall-after-judge-sides-with-arbutus-patent-fight-2024-04-03/ |access-date=2024-05-19 |work=Reuters}}</ref> In April 2023, a court affirmed a decision to cancel a patent by [[Arbutus Biopharma]] in connection with the dispute.<ref>{{Cite news | url=https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-fends-off-arbutus-appeal-covid-19-vaccine-patent-fight-2023-04-11/ | title=Moderna fends off Arbutus appeal in COVID-19 vaccine patent fight | first=Blake | last=Brittain | work=[[Reuters]] | date=April 11, 2023}}</ref> In April 2024, however, the court issued an order that strengthened Arbutus's arguments by interpreting patents at issue in the manner Arbutus had urged.<ref name=\":0\" />\n\nSeveral legal cases between Moderna and [[Pfizer]] and [[BioNTech]] in various countries, alleging that the [[Pfizer\u2013BioNTech COVID-19 vaccine]] violates the patent on Moderna's [[mRNA vaccine]] technology, are ongoing.<ref>{{Cite news |last1=Robbins |first1=Rebecca |last2=Gross |first2=Jenny  |title=Moderna Sues Pfizer and BioNTech Over Covid Vaccine Technology |url=https://www.nytimes.com/2022/08/26/business/moderna-covid-vaccine-lawsuit.html |work=[[The New York Times]] |date=August 26, 2022 |issn=0362-4331}}</ref>\n\n=== Legal Disputes ===\nIn November 2024, British pharmaceutical company [[GSK plc|GlaxoSmithKline (GSK)]] filed a lawsuit against Moderna Inc. in a U.S. federal court in [[Delaware]], alleging that Moderna's COVID-19 vaccine [[Moderna COVID-19 vaccine|Spikevax]] and RSV vaccine mResvia infringe on GSK\u2019s patents related to messenger RNA (mRNA) technology. According to the complaint, Moderna's use of lipid nanoparticles\u2014crucial for delivering fragile mRNA into the human body\u2014violates several GSK patents covering similar delivery innovations.<ref name=\":1\">{{Cite news |last=Brittain |first=Blake |date=16 October 2024 |title=GSK sues Moderna for US patent infringement over COVID, RSV vaccines |url=https://www.reuters.com/business/healthcare-pharmaceuticals/glaxosmithkline-sues-moderna-us-patent-infringement-over-covid-vaccines-2024-10-15/ |access-date=8 November 2024 |work=Reuters}}</ref>\n\nThis lawsuit follows a similar legal action GSK brought against Pfizer and BioNTech earlier in 2024, claiming patent infringement over their mRNA-based COVID-19 vaccine. GSK\u2019s latest litigation seeks unspecified monetary damages from Moderna.<ref name=\":1\" />\n\n=== Rare disease therapeutics ===\n{{Empty section|date=September 2024}}\n==Financial data==\n{| class=\"wikitable float-left\" style=\"text-align: right;\"\n|-\n!Year\n!Revenue<br />(mln. US$)\n!Net income (loss)<br />(mln. US$)\n|-\n|2019<ref name=10K/>\n|60\n|(514)\n|-\n|2020<ref name=10K/>\n|803\n|(747)\n|-\n|2021<ref name=10K/>\n|18,471\n|12,202\n|-\n|2022<ref name=10K/>\n|19,263\n|8,362\n|-\n|2023<ref name=10K/>\n|6,848\n|(4,710)\n|}\n\n==See also==\n* [[DNA vaccine]]\n* [[CureVac]]\n\n==References==\n{{reflist}}\n\n==External links==\n{{commons category}}\n* {{Official website}}\n{{Finance links\n| name = Moderna, Inc.\n| symbol    = MRNA\n| google    = MRNA:NASDAQ\n| yahoo     = MRNA\n| bloomberg = MRNA:US\n| reuters   = MRNA.O\n| sec_cik   = 1682852\n}}\n\n{{Pharmaceutical companies of the United States}}\n\n{{authority control}}\n\n[[Category:Moderna| ]]\n[[Category:2010 establishments in Massachusetts]]\n[[Category:2018 initial public offerings]]\n[[Category:American companies established in 2010]]\n[[Category:Biotechnology companies of the United States]]\n[[Category:Biotechnology companies established in 2010]]\n[[Category:Companies based in Cambridge, Massachusetts]]\n[[Category:Companies listed on the Nasdaq]]\n[[Category:Health care companies based in Massachusetts]]\n[[Category:COVID-19 vaccine producers]]\n[[Category:Medical research]]\n[[Category:Pharmaceutical companies of the United States]]"}